KR20160058212A - Health supplements composition containing concentrated black ginseng for menopausal women - Google Patents
Health supplements composition containing concentrated black ginseng for menopausal women Download PDFInfo
- Publication number
- KR20160058212A KR20160058212A KR1020140149690A KR20140149690A KR20160058212A KR 20160058212 A KR20160058212 A KR 20160058212A KR 1020140149690 A KR1020140149690 A KR 1020140149690A KR 20140149690 A KR20140149690 A KR 20140149690A KR 20160058212 A KR20160058212 A KR 20160058212A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- black ginseng
- bone
- present
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 70
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 70
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 70
- 241000208340 Araliaceae Species 0.000 title claims abstract 6
- 235000015872 dietary supplement Nutrition 0.000 title description 2
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 23
- 235000013376 functional food Nutrition 0.000 claims abstract description 22
- 239000012141 concentrate Substances 0.000 claims abstract description 11
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 10
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 8
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 7
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims abstract description 6
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 6
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract description 6
- 229960002733 gamolenic acid Drugs 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 20
- 235000002789 Panax ginseng Nutrition 0.000 claims description 14
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 7
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 6
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 5
- 241001105098 Angelica keiskei Species 0.000 claims description 4
- 235000017803 cinnamon Nutrition 0.000 claims description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
- 244000170916 Paeonia officinalis Species 0.000 claims description 3
- 210000004207 dermis Anatomy 0.000 claims description 3
- 240000001810 Angelica gigas Species 0.000 claims description 2
- 235000018865 Angelica gigas Nutrition 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 240000001949 Taraxacum officinale Species 0.000 claims 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 230000006872 improvement Effects 0.000 abstract description 10
- 230000003859 lipid peroxidation Effects 0.000 abstract description 9
- 230000037182 bone density Effects 0.000 abstract description 5
- 241000411851 herbal medicine Species 0.000 abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 230000004153 glucose metabolism Effects 0.000 abstract description 4
- 230000037356 lipid metabolism Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 235000008504 concentrate Nutrition 0.000 abstract description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 65
- 210000000988 bone and bone Anatomy 0.000 description 46
- 230000000694 effects Effects 0.000 description 35
- 238000012360 testing method Methods 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 239000000126 substance Substances 0.000 description 23
- 229910052500 inorganic mineral Inorganic materials 0.000 description 21
- 239000011707 mineral Substances 0.000 description 21
- 239000011575 calcium Substances 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 16
- 235000013305 food Nutrition 0.000 description 14
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
- 108010082126 Alanine transaminase Proteins 0.000 description 13
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 102000004067 Osteocalcin Human genes 0.000 description 10
- 108090000573 Osteocalcin Proteins 0.000 description 10
- 208000001132 Osteoporosis Diseases 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 230000009245 menopause Effects 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102000005720 Glutathione transferase Human genes 0.000 description 7
- 108010070675 Glutathione transferase Proteins 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000009806 oophorectomy Methods 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100021253 Antileukoproteinase Human genes 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004097 bone metabolism Effects 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 229930182494 ginsenoside Natural products 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 244000018764 Nyssa sylvatica Species 0.000 description 4
- 235000003339 Nyssa sylvatica Nutrition 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008416 bone turnover Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 240000006432 Carica papaya Species 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- HOURAEXAZWBEAW-UHFFFAOYSA-N 1-aminopropane-1,1,3-tricarboxylic acid Chemical compound OC(=O)C(C(O)=O)(N)CCC(O)=O HOURAEXAZWBEAW-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- JTWUZULPZAALRN-UHFFFAOYSA-N 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carbaldehyde;phosphoric acid Chemical compound OP(O)(O)=O.CC1=NC=C(CO)C(C=O)=C1O JTWUZULPZAALRN-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 229940123861 Bone formation stimulant Drugs 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 241000238578 Daphnia Species 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000788084 Escualosa thoracata Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- -1 ginsenoside Rg3 Chemical compound 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013446 pixi Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0085—Substances of natural origin of unknown constitution, f.i. plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 흑삼 농축액을 포함하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물에 관한 것으로서, 좀 더 자세히는 흑삼 농축액, 감마리놀렌산, 이소플라본 외에 당귀, 천궁, 작약, 숙지황, 진피, 갈근, 황기, 계피, 단삼, 백하수오 및 애엽의 한방 생약 추출물이 조합된 여성 갱년기 증상의 개선 및 예방에 유효한 조성물에 관한 것이다. 본 발명의 조성물은 혈당 및 지질대사를 개선하고, 골밀도를 증가시키며, 항산화 활성을 나타내며 지질 과산화를 억제하였다.The present invention relates to a health functional food composition for improving the symptoms of women's menopausal symptoms comprising a black ginseng concentrate. More specifically, the present invention relates to a health functional food composition for improving the symptoms of women's menopausal symptoms, which comprises black ginseng concentrate, gamma linolenic acid, isoflavone, The present invention relates to a composition effective for the improvement and prevention of female menopausal symptoms in combination with herbal medicine extracts of Danshen, Baekhwa and Leaf. The composition of the present invention improves blood glucose and lipid metabolism, increases bone density, exhibits antioxidant activity, and inhibits lipid peroxidation.
Description
본 발명은 흑삼 농축액을 포함하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물에 관한 것으로서, 좀 더 자세히는 흑삼 농축액, 감마리놀렌산, 이소플라본 외에 당귀, 천궁, 작약, 숙지황, 진피, 갈근, 황기, 계피, 단삼, 백하수오 및 애엽의 11종 한방 생약 추출물이 조합된 여성 갱년기 증상의 개선 및 예방에 유효한 조성물에 관한 것이다. 본 발명의 조성물은 혈당 및 지질대사를 개선하고, 골밀도를 증가시키며, 항산화 활성을 나타내며 지질 과산화를 억제하였다.The present invention relates to a health functional food composition for improving the symptoms of women's menopausal symptoms comprising a black ginseng concentrate. More specifically, the present invention relates to a health functional food composition for improving the symptoms of women's menopausal symptoms, which comprises black ginseng concentrate, gamma linolenic acid, isoflavone, The present invention relates to a composition effective for the improvement and prevention of female menopausal symptoms in combination with eleven kinds of herbal medicine extracts. The composition of the present invention improves blood glucose and lipid metabolism, increases bone density, exhibits antioxidant activity, and inhibits lipid peroxidation.
최근 우리나라의 여성 사회 참여율과 지위가 급상승하고 있으며, 경제활동 여성이 1000만명을 넘었다. 현재 여성의 평균수명 또한 남자보다 약 4∼5년 정도 많은 평균 80세를 지나고 있는 실정이다. 이와 같이 여성의 평균수명의 연장과 지적수준의 향상 등으로 여성의 폐경기와 폐경 후의 삶의 질 향상과 건강 증진에 대한 관심이 고조되고 있다. 일반적으로 폐경기를 전후한 갱년기 증상은 그 자체로 특별한 질병은 아니며 단순히 신체적으로 허약할 때 나타나는 증상들과 유사하여 개인 스스로 그 증상의 정도를 깊이 인식하고 적극적으로 적응하려는 노력이 없으면 방치되기 쉬운 특징을 지니고 있어, 일상생활을 하는데 고통을 주기도 한다.Recently, the participation rate and status of women in the Korean society has increased rapidly, and more than 10 million women are active in economic activities. Currently, the average life span of women is about 80 years old, which is about 4-5 years longer than that of men. In this way, the life expectancy of women and the improvement of their intellectual level have raised the interest in improving the quality of life and health promotion of postmenopausal women and postmenopausal women. In general, menopausal symptoms before and after menopause are not special diseases in themselves, and they are similar to symptoms that appear when they are physically fragile. Therefore, if you are not aware of the extent of the symptoms yourself and actively adapt to it, I am carrying it, and it is painful to do everyday life.
갱년기는 폐경의 문제로 여러 신체 조직에 영향을 주어 골다공증, 심혈관계 질환, 비뇨생식기계 이상 등 다양한 문제를 초래할 뿐만 아니라 암과 기타 만성질환에 이환되기 쉬운 갱년기는 건강상 위기의 시기로 고려되기도 한다. 이러한 갱년기 증상 중 특히 심혈관계 질환과 골다공증 등은 여성의 생명에 직접적으로 영향을 주는 위험한 만성 휴유증이 발생할 수 있다. 폐경기를 지나 장년기에서 노년기에 이르면 심폐기능의 저하와 더불어 근 골격에서도 근 질량과 근력이 감소하고 인대와 건이 약화되며 관절의 유동성이 저하된다. 특히 여성은 40세를 넘어서면서 점차 월경주기가 불규칙해지거나 출혈 양에도 변화가 오기 시작하며, 여러 가지 부정적인 신체적 변화를 경험하게 되고 폐경기 이후부터는 에스트로겐의 분비가 중단되면서 골 소실로 인한 골다공증 현상이 두드러지게 된다. 골다공증은 골무기질과 골량이 저하된 상태로 골조직의 미세구조가 변화되거나 그것으로 인하여 골이 유약해져 골절이 되기 쉬운 상태이며 폐경 이후의 여성에게서는 골밀도가 급속하게 저하되고, 폐경 후 10년 사이에 약 20%의 골 무기질이 감소한다. 골(bone)의 대사는 성장기는 물론, 성장이 끝난 성인에게서 새로운 뼈가 오래된 뼈를 대체하는 생성과 흡수과정을 지속적으로 반복하면서 골 재형성(bone remodeling) 과정에 의해 유지하게 되는데, 성별이나 연령층에 비하여 골밀도와 골 질량이 감소하고 골절의 감수성이 증가한 상태 즉, 골 항상성 기전의 이상이 발생하면 골 대사 질환인 골다공증이 유발된다. 특히 폐경기 여성들의 경우 난소기능의 저하로 인해 에스트로겐 분비가 감소함으로써 파골세포의 증식 및 활성을 증가시켜 골 흡수를 촉진하기 때문에 골다공증이 유발된다고 한다.Menopause is a problem of menopause that affects various body tissues and causes various problems such as osteoporosis, cardiovascular disease, genitourinary disorder, etc., and menopause, which is easily affected by cancer and other chronic diseases, is considered as a period of health crisis. These menopausal symptoms, especially cardiovascular disease and osteoporosis, can cause dangerous chronic sequelae that directly affect the life of women. After menopause, there is a decline in cardiopulmonary function and a decrease in muscular mass and strength in muscular skeleton, weak ligament and tendon, and decreased fluidity of joint. Especially, women are over 40 years old, and menstruation cycle becomes irregular, bleeding volume starts to change, and various negative physical changes are experienced. After menopause, estrogen secretion is stopped and osteoporosis due to bone loss is prominent . Osteoporosis is a condition in which the bone mineral content and bone mass are decreased, and the microstructure of the bone tissue is changed. As a result, the bone is weak and the bone is prone to fracture. In postmenopausal women, the bone mineral density rapidly decreases. 20% of bone mineral is reduced. Metabolism of bone is maintained by bone remodeling process, continuously repeating the generation and absorption process in which new bone replaces old bone in growing adult as well as growing age, The bone mineral density and bone mass are decreased and the susceptibility of the fracture is increased, that is, when the abnormality of the osteoarthritic mechanism occurs, osteoporosis which is a bone metabolic disease is induced. Especially in postmenopausal women, estrogen secretion is reduced due to a decrease in ovarian function, thereby promoting osteoporosis because osteoclast proliferation and activity are increased to promote bone resorption.
골다공증 치료제는 골 흡수 억제제와 골 형성 자극제로 나눌 수 있다. 골 흡수 억제제로는 칼슘, 에스트로겐, 칼시토닌, 비스포스포네이트, 비타민 D 등이 있으며, 골 흡수를 억제하여 골 교체율을 감소시킨다. 골 흡수와 골 형성은 밀접하게 연결되어 있기 때문에 골 흡수 억제제를 사용한 지 수 개월 후 새로운 평형상태에 도달하며 골 형성도 감소하게 된다. 골량을 증가시키는 골 형성 자극제로는 현재 부갑상선 호르몬이 유일하였으나, 최근 스트론튬 라넬레이트(strontium ranelate)가 추가되었다.Osteoporosis drugs can be divided into bone resorption inhibitors and bone formation stimulants. Bone resorption inhibitors include calcium, estrogen, calcitonin, bisphosphonate, and vitamin D, which inhibit bone resorption and reduce bone turnover rate. Since bone resorption and bone formation are closely linked, a new equilibrium state is reached several months after using the bone resorption inhibitor, and bone formation is also reduced. At present, parathyroid hormone is the only osteogenic stimulator that increases bone mass, but recently strontium ranelate has been added.
그러나, 현재의 치료제들은 여러 가지 부작용을 초래하고 있어 사용에 한계가 있다. 대표적인 칼슘제제의 경우 필요 이상의 칼슘을 섭취하는 경우 칼슘 배설의 증가로 인해 요로 결석이 발생할 수 있고, 골 흡수 억제제로 사용하는 대표적인 약물인 에스트로겐의 경우 관상동맥과 뇌졸중과 같은 심혈관계 질환의 위험이 있다. 칼시토닌의 경우 주사 또는 비강분무를 해야 한다는 사용상의 불편함과 내성의 문제가 있다. 비스포스포네이트의 경우 위장관 증상으로 오심, 구토, 소화불량 등의 부작용이 발생할 수 있다.
However, the present therapeutic agents cause various side effects, and their use is limited. In the case of representative calcium preparations, urinary stones may occur due to an increase in calcium excretion when calcium is ingested more than necessary, and estrogen, a representative drug used as a bone resorption inhibitor, is at risk of cardiovascular diseases such as coronary artery and stroke . In the case of calcitonin, there is a problem of inconvenience and resistance to use, such as injection or nasal spray. In the case of bisphosphonates, gastrointestinal symptoms may cause side effects such as nausea, vomiting, and indigestion.
고려인삼은 동아시아 지역에서 적어도 2000년 이상의 오랜 약용 역사가 있으며, 항암, 항당뇨, 고지혈증 개선, 간의 해독작용 촉진, 독성물질 해독작용, 신장기능 촉진, 항산화 활성 및 노화 억제 등의 효과가 보고되었다. 가벼운 갱년기 증상을 나타내는 여성을 대상으로 한 임상실험에서 홍삼의 유효성을 평가한 결과 유효성이 인정되었다. KOREA INSAM has a long history of medicinal use in East Asia for at least 2000 years and has been reported to have effects such as anticancer, anti-diabetic, hyperlipidemia, promotion of liver detoxification, toxic substance detoxification, promotion of renal function, antioxidant activity and inhibition of aging. The efficacy of red ginseng in clinical trials for women with mild menopausal symptoms was evaluated.
홍삼추출물에 함유된 페놀성 물질과 홍삼의 비사포닌 성분들은 생체의 지질 과산화 억제작용, 산화적 스트레스 방어효과 등 항노화 효능이 있음이 예로부터 현재에 이르기까지 수많은 연구를 통하여 보고된 바 있다. 흑삼은 홍삼 내에 다량으로 존재하는 진세노사이드 Rb, Rc, Rd, Re, Rg1 등이 제조과정 중 열분해 되어 진세노사이드 Rg2, Rg3, Rh 등으로 전환되고 있으며, 특히 진세노사이드 Rg3 함량이 강화되어 있는데 많은 경우 8 mg/g 이상을 함유한다고 한다. 흑삼의 주요 효능으로는 자양·강장효과, 성기능 및 생식기능 부전 개선 효과, 항암효과, 간장기능 부전 개선 효과, 숙취해소 효과, 기생충 감염 방지효과, 진통·소염 작용 등이 있는 것으로 알려져 있다.Phenolic substances in red ginseng extract and non - saponin components of red ginseng have been reported through many studies from the past to the present since the antioxidative effect such as the lipid peroxidation inhibitory action and the oxidative stress defense effect in the living body. The ginsenosides Rb, Rc, Rd, Re, and Rg1, which are present in a large amount in red ginseng, are converted into ginsenosides Rg2, Rg3, Rh and the like by pyrolysis during the production process. Especially, the content of ginsenoside Rg3 is enhanced In many cases, it is said to contain more than 8 mg / g. The main effects of black ginseng are known to be nourishing and tonic effects, sexual function and improvement of reproductive dysfunction, anti-cancer effect, improvement of hepatic dysfunction, hangover resolution effect, parasitic infection prevention effect, analgesic and anti-inflammatory effect.
본 발명자들이 확인한 결과, 흑삼은 진세노사이드 함량이 증가하여 기능성이 높아지는 것으로 밝혀졌으며 특히 진세노사이드 Rg3가 더 많이 증가함을 확인하였다. 그러나, 흑삼의 갱년기 증상 개선에 관해서는 지금까지 구체적인 연구 결과가 없는 실정이다.
As a result of confirming by the inventors, it was found that the black ginseng has an increased functionality due to an increase in ginsenoside content, and especially ginsenoside Rg3 is increased. However, there is no specific study on the improvement of menopausal symptom of black ginseng until now.
본 발명은 여성 갱년기 증상 개선에 효과적인 건강기능성 식품 조성물을 제공하려는 것을 목적으로 한다.It is an object of the present invention to provide a health functional food composition effective for improving female menopausal symptoms.
본 발명의 목적은 진세노사이드 Rg3를 비롯한 생리활성물질의 함량이 높아지고 소화와 흡수력이 증가된 흑삼 및 천궁, 당귀, 작약, 숙지황, 백하수오 등 한방 생약재와 이소플라본 등을 이용하여 여성 갱년기 증상 개선용 건강기능성 식품을 제공하려는 것이다.It is an object of the present invention to improve women's menopausal symptoms by using herbal medicine and isoflavone such as ginsenoside Rg3, physiologically active substance, increased digestion and absorption, and ginseng herb, ginseng, angelica, And to provide health functional foods for health.
지금까지는 중년 여성의 갱년기 증상 개선용 건강기능성 식품으로 흑삼을 함유한 제품이 출시된 바 없었다. 본 발명자들은 진세노사이드 Rg3가 증가된 흑삼을 주원료로 한 시제품을 개발하였으며, 본 발명의 여성 갱년기 증상 개선용 건강기능성 식품 조성물은 홍삼의 기능은 물론 흑삼 고유의 기능(치매에 효과가 있으며 항 감기바이러스 기능, 항산화 기능)이 더해져서 갱년기 증상이 개선되고 몸에 활력을 준다.Until now, there has been no product containing black ginseng as health functional food for middle-aged women to improve the symptoms of menopause. The inventors of the present invention developed a prototype product in which black ginseng as an main ingredient was increased in ginsenoside Rg3, and the health functional food composition for improving the female menopausal symptom of the present invention is effective for the function of the red ginseng as well as the function of the red ginseng Virus function, antioxidant function) is added to improve the symptoms of menopause and gives vitality to the body.
본 발명자들은 생리활성물질인 진세노사이드 함량을 증대시킨 흑삼 조성물로 최적화 여성 갱년기 증상 개선용 건강기능성 식품을 발명하고, 난소 절제동물모델을 이용한 인 비보 실험을 통하여 본 발명의 흑삼 조성물이 지질 대사, 골밀도 등 여러 가지 생체지표를 개선함을 밝혔다. 또한, 종래 골다공증을 포함하는 여성 갱년기 증상 치료용 약제의 사용이 다양한 부작용을 초래하였으나, 이미 홍삼에서 많은 연구가 이루어져 여성갱년기 증상 개선에 대하여 부작용의 사례가 보고된바 없으며, 본 발명의 흑삼 조성물을 구성하는 구성성분들은 종래 널리 사용되던 한방 생약재 및 생리활성물질들이므로 부작용이 없을 것으로 예상된다.
The inventors of the present invention invented a health functional food for optimizing female menopausal symptom by using a black ginseng composition which increased the content of ginsenoside, which is a physiologically active substance. Through the in vivo test using an ovariectomized animal model, Bone mineral density and other biomarkers. In addition, although the use of medicines for treatment of female menopausal symptoms including osteoporosis has caused various side effects, many studies have already been made on red ginseng, and no cases of side effects have been reported on the improvement of female menopausal symptoms. It is expected that there will be no side effects since the components constituting the composition are conventionally widely used herbal medicines and physiologically active substances.
상기 과제를 해결하기 위하여 본 발명자들은 흑삼 농축액, 감마리놀렌산, 대두유, 이소플라본 외에 당귀, 천궁, 작약, 숙지황, 진피, 갈근, 황기, 계피, 단삼, 백하수오 및 애엽의 11종 한방 생약 추출물을 조합하여 여성 갱년기 증상의 개선 및 예방에 유효한 조성물을 제조하였다.In order to solve the above-mentioned problems, the inventors of the present invention found that a combination of herbal medicine extracts of 11 kinds of herb medicine such as Angelica gigas, Angelica keiskei, Thereby preparing a composition effective for the improvement and prevention of female menopausal symptoms.
좀 더 구체적으로 본 발명은 진세노사이드 Rg1, Rb1, Rg3의 합이 6 ㎎/g 이상, 바람직하게는 6~30 ㎎/g인 흑삼 농축액, 감마리놀렌산, 이소플라본, 당귀, 천궁, 작약, 숙지황, 진피, 갈근, 황기, 계피, 단삼, 백하수오 및 애엽 각 추출물을 포함하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물에 관한 것이다.More specifically, the present invention relates to a method for the production of ginsenosides Rg1, Rb1 and Rg3, wherein the sum of ginsenosides Rg1, Rb1 and Rg3 is 6 mg / g or more, preferably 6 to 30 mg / g, The present invention relates to a health functional food composition for improving women's menopausal symptoms, which comprises an extract of a dermis, a papaya root, a papaya, a cinnamon, a daphnia, a bagasse and a leaf extract.
또한, 본 발명은 진세노사이드 Rg1, Rb1 및 Rg3의 합이 6 ㎎/g 이상, 바람직하게는 6~30 ㎎/g인 흑삼 농축액 5~30중량%, 감마리놀렌산 20~40중량%, 이소플라본 2~6중량%, 당귀, 천궁, 작약, 숙지황, 진피, 갈근, 황기, 계피, 단삼, 백하수오 및 애엽 각 추출물 1~5중량%를 포함하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물에 관한 것이다. 각 구성성분의 상대적 혼합비가 위와 같을 때에 골밀도 개선, 혈행 개선, 항산화 효과 등이 우수하며, 섭취가 용이하고, 제형 형성이 용이하다.The present invention also relates to a method for producing a white ginseng concentrate comprising 5 to 30% by weight of a ginseng concentrate having a sum of ginsenosides Rg1, Rb1 and Rg3 of 6 mg / g or more, and preferably 6 to 30 mg / g, 20 to 40% The present invention relates to a health functional food composition for improving female menopausal symptoms comprising 2 to 6% by weight of Angelica gigantosa, Angelica keiskei keiskei, Peony root, Safflower, Dermis, Puerariae radix, Cinnamon, Cinnamomum, . When the relative mixing ratio of each component is as described above, it is excellent in bone density improvement, blood circulation improvement, antioxidant effect, etc., easy ingestion, and easy formulation.
또한, 본 발명은 상기 조성물에 대두유를 가하는 것을 특징으로 하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물에 관한 것이다.The present invention also relates to a health functional food composition for improving female menopausal symptoms characterized by adding soybean oil to the composition.
본 발명 조성물 중 이소플라본은 골 건강에 도움이 되는 것으로 알려져 있다. 감마리놀렌산은 혈중 콜레스테롤을 개선하고 혈행을 개선한다. 당귀, 천궁, 작약, 숙지황은 보혈작용이 있어 피를 보충해 주며, 단삼은 혈액순환, 어혈 제거, 항산화 효과가 있으며, 애엽은 노화 방지, 면역력 증가, 항균작용이 있다. 백하수오는 여성호르몬 감소에 의한 여성 건강 저하를 개선할 수 있다. 흑삼 농축액은 면역력 증진, 피로 개선, 기억력 개선, 혈소판 응집 억제를 통한 혈행 개선, 항산화에 도움을 준다.
Isoflavones in the compositions of the present invention are known to be beneficial to bone health. Gamma linolenic acid improves blood cholesterol and improves circulation. It has blood circulation, eosinophilia, antioxidant effect, and anti-aging effect, anti-aging effect, anti-bacterial effect. White Saury can improve female health deterioration due to female hormone reduction. The black ginseng concentrate helps improve immunity, improve fatigue, improve memory, improve blood circulation by inhibiting platelet aggregation, and help antioxidants.
본 발명에서 "식품"은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 각종 식품, 건강기능 식품, 음료, 식품 첨가제 및 음료 첨가제를 모두 포함하는 의미로 사용된다. 상기 식품의 예로서 각종 식품류, 음료, 껌, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영, 유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실,채소류 음료, 두유류, 발효음료류, 아이스크림류 등), 천연조미료(예, 라면 스프 등), 비타민 복합제, 알코올 음료, 주류 및 그 밖의 건강보조식품류를 포함하나 이에 한정되지 않는다. 상기 건강기능식품, 음료, 식품첨가제 또는 음료첨가제는 통상의 제조방법으로 제조될 수 있다.The term "food" in the present invention means a natural product or a processed product containing one or more nutrients, preferably a state of being able to be eaten directly through a certain processing step, It is used to include all foods, health functional foods, beverages, food additives and beverage additives. Examples of the food include various foods, beverages, gums, tea, vitamin complex, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, natural flavors (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages and other health supplement foods. The health functional food, beverage, food additive or beverage additive can be produced by a usual production method.
상기 식품 조성물은 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The food composition may comprise a pharmaceutically acceptable food-aid additive and may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of a functional food.
또한, 상기 식품에 있어서, 상기 흑삼 조성물의 양은 전체 식품 중량의 0.001 중량% 내지 50 중량%로 포함될 수 있으며, 상기 식품이 음료인 경우에는 식품 전체의 부피 100 ㎖를 기준으로 0.001 g 내지 50 g, 바람직하게는 0.01 g 내지 10 g의 비율로 포함될 수 있으나, 이에 한정되는 것은 아니다.In the food, the amount of the black ginseng composition may be 0.001 to 50% by weight of the total food. When the food is a beverage, the amount of the black ginseng composition is 0.001 to 50 g, Preferably 0.01 to 10 g, but is not limited thereto.
본 발명의 흑삼 조성물을 포함하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물은 정제형, 캡슐형, 진액형, 분말형, 음료형, 스틱형 등 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 널리 알려진 다양한 제형으로 제조 가능하다.
The health functional food composition for improving female menopausal symptoms comprising the black germicidal composition of the present invention may be in the form of tablets, capsules, lozenges, powders, beverages, sticks, and the like to those skilled in the art It can be manufactured in a wide variety of known formulations.
본 발명의 여성 갱년기 증상 개선용 건강기능성 식품 조성물은 난소를 절제한 동물군에 대하여 혈당 및 지질대사를 개선하고, 골밀도를 증가시키며, 골 중 무기질 성분을 증대시키고, 항산화 활성을 나타내며 지질 과산화를 억제하였다. 특히, 본 발명 흑삼 조성물의 이와 같은 효과는 현재 시중에서 시판되는 홍삼 및 백하수오를 주요 성분으로 하는 대표적인 여성 갱년기 증상 개선용 건강기능성 식품에 비하여 그 효능이 유사하거나 좀 더 우수하였다. The health functional food composition for improving female menopausal symptoms according to the present invention can improve blood glucose and lipid metabolism, increase bone mineral density, increase mineral content of bone, exhibit antioxidative activity and inhibit lipid peroxidation in an ovariectomized animal group Respectively. In particular, the effect of the present invention of black ginseng composition is similar or better than that of a typical health-functional food for improving female menopausal symptoms, which is commercially available red ginseng and white sardine.
도 1은 본 발명의 흑삼 조성물이 골밀도에 미치는 영향을 나타낸 그래프이다. 이하에서 도면 및 표에서 normal control: 정상대조군, sham: 샴군, OVX: 난소절제군, D100: 본 발명의 흑삼 조성물 저농도 투여군(100㎎/g), D300: 본 발명의 흑삼 조성물 고농도 투여군(300㎎/g), K100: 대조시험물질 저농도 투여군(100㎎/g), K300: 대조시험물질 고농도 투여군(300㎎/g)을 나타낸다.
도 2는 본 발명의 흑삼 조성물이 당 및 지질대사에 미치는 영향을 나타낸 그래프이다. T.CHO: 총콜레스테롤.
이하 도면 및 표에서 *, ** 등 별표는 정상대조군과 유의하게 다름을 나타내며 (P<0.05∼0.01), #, ## 등 우물정 표시는 난소절제군과 유의하게 다름을 나타낸다 (P<0.05∼0.01).
도 3은 본 발명의 흑삼 조성물이 골 무기물에 미치는 영향을 나타낸 그래프이다.
도 4는 본 발명의 흑삼 조성물이 요중 골 무기질(Ca 및 P)에 미치는 영향을 나타낸 그래프이다.
도 5는 본 발명의 흑삼 조성물이 혈중 호르몬과 골 대사 지표에 미치는 영향을 나타낸 그래프이다.
도 6은 본 발명의 흑삼 조성물이 사이토카인 농도에 미치는 영향을 나타낸 그래프이다.
도 7은 본 발명의 흑삼 조성물이 항산화 효소에 미치는 영향을 나타낸 그래프이다.
도 8은 본 발명의 흑삼 조성물이 지질 과산화에 미치는 영향을 나타낸 그래프이다.1 is a graph showing the effect of the black ginseng composition of the present invention on bone mineral density. (100 mg / g) of the present invention, D300: high concentration group of the black ginseng composition of the present invention (300 mg / day) / g), K100: low control group (100 mg / g), and K300: high control group (300 mg / g).
FIG. 2 is a graph showing the effect of the black ginseng composition of the present invention on glucose and lipid metabolism. T.CHO: total cholesterol.
In the following figures and tables, asterisks such as * and ** indicate significant differences from normal control group (P <0.05-0.01), and well markings such as # and ## are significantly different from ovariectomized group (P <0.05 ~ 0.01).
FIG. 3 is a graph showing the effect of the black ginseng composition of the present invention on bone mineral.
4 is a graph showing the effect of the black ginseng composition of the present invention on urinary bone mineral (Ca and P).
FIG. 5 is a graph showing the effect of the black ginseng composition of the present invention on blood hormones and bone metabolism index.
6 is a graph showing the effect of the black ginseng composition of the present invention on cytokine concentration.
7 is a graph showing the effect of the black ginseng composition of the present invention on antioxidant enzymes.
8 is a graph showing the effect of the black ginseng composition of the present invention on lipid peroxidation.
아래에서는 구체적인 실시예를 들어 본 발명의 구성을 좀 더 자세히 설명한다. 그러나, 본 발명의 범위가 아래 실시예의 기재범위 내로 한정되는 것이 아님은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 자명하다. Hereinafter, the configuration of the present invention will be described in more detail with reference to specific embodiments. However, it is apparent to those skilled in the art that the scope of the present invention is not limited to the scope of the following embodiments.
이하에서 normal control은 정상대조군, sham은 샴군, OVX는 난소절제군, D100은 본 발명의 흑삼 조성물 저농도 투여군(100㎎/g), D300은 본 발명의 흑삼 조성물 고농도 투여군(300㎎/g), K100은 대조시험물질 저농도 투여군(100㎎/g), K300은 대조시험물질 고농도 투여군(300㎎/g)을 의미하는 약자로 사용하였다.
(100 mg / g) of the present invention, D300 is a high concentration group of the black ginseng composition (300 mg / g) of the present invention, K100 was used as an abbreviation for the low-dose control group (100 mg / g) and K300 was used as the abbreviation for the high-dose group (300 mg / g) of the control test substance.
흑삼 제조Black ginseng manufacturing
4~6년근 홍삼을 미삼만 분리하여 90~98℃에서 85~100분간 증숙하고, 40~48℃에서 2시간 건조하였다. 이 과정이 1증 1포인데, 이 과정을 5회 내지 9회 수행하였다. 이 과정을 거친 삼을 자연숙성하여 최종적으로 흑미삼을 제조하였다.Only 4 ~ 6 years old red ginseng was separated and dried at 90 ~ 98 ℃ for 85 ~ 100 minutes and dried at 40 ~ 48 ℃ for 2 hours. This process is one vial, and this process was performed five to nine times. This process has been naturally aged to finally produce black rice flour.
진세노사이드 10여종 외 기능성 성분 함량에 대하여 동진제약 식품사업부 부설연구소 자체 검사 및 공인기관 검사 결과 흑삼의 진세노사이드 함량이 증가되어 홍삼보다 기능성이 우수해짐을 확인하였다.About 10 kinds of ginsenosides and other functional ingredients The results of self-inspection and official laboratory tests of Dongjin Pharma Foods Division showed that the ginsenoside content of black ginseng was higher than that of red ginseng.
위와 같이 얻은 흑삼을 75~80℃의 정제수 또는 알콜로 추출하고 60~65℃로 감압 농축하여 흑삼 농축액을 제조하였다.
The thus-obtained black ginseng was extracted with purified water or alcohol at 75 to 80 ° C and concentrated under reduced pressure at 60 to 65 ° C to prepare a black ginseng concentrate.
대조시험물질Control test substance
이하 본 발명의 실시예 및 결과에서 K100 및 K300으로 표시되는 대조시험물질은 백하수오 추출물과 홍삼 농축액 (진세노사이드 Rg1+Rb1 4.5 ㎎/g)을 주요 성분으로 하여 시판 중인 여성 갱년기 증상 개선용 건강기능성 식품이다.
In the examples and results of the present invention, the test substance represented by K100 and K300 was prepared by using a white sachet extract and a red ginseng concentrate (ginsenoside Rg1 + Rb1 4.5 mg / g) as main components, It is a functional food.
시험물질 제조Manufacture of Test Materials
본 발명의 흑삼 조성물은 흑삼 농축액 (진세노사이드 Rg1+Rb1+Rg3의 합 8.4 ㎎/g) 20중량%, 감마리놀렌산 24중량%, 이소플라본 6중량% 외에 당귀, 천궁, 숙지황, 작약, 단삼, 백하수오 추출물 각 5중량%씩과 진피, 갈근, 황기, 계피 및 애엽 추출물 각 4중량%씩을 조합하여 제조하였다.
The black ginseng composition of the present invention contains 20 wt% of a black ginseng concentrate (ginsenoside Rg1 + Rb1 + Rg3 in total of 8.4 mg / g), 24 wt% of gamma linolenic acid, 6 wt% of isoflavone, 5% by weight of white sachet extract, and 4% by weight of each of dyestuff, purl, yellow, cinnamon and lavender extracts.
실험동물Experimental animal
SD (Sprague-Dawley)계 5주령의 암컷 랫트를 (주)샘타코바이오코리아(경기도 오산)로부터 구입하여 4주 동안 사육장과 조제사료에 순화기간을 거쳐 260 g 정도 되었을 때 건강한 동물만을 골라 실험에 사용하였다. 본 발명의 흑삼 조성물 시험은 정상대조군 (normal control), 샴군 {sham-operation, 펜토바비탈 나트륨 (entobal, 한림제약)으로 마취 (50 mg/kg. bw, ip)한 다음 등쪽의 피부만 절개하여 개복한 군, 난소 적출군 (ovariectomized group, OVX군, 양쪽의 난소를 모두 절제함)과 대조시험군인 K100, K300과 동일한 조건으로 수행하였다. 수술 후 모든 공시동물은 감염을 방지하기 위해 황산 겐타마이신 주사액 (겐타마이신 주, 동신제약)을 1회 투여 (0.2 mg/kg.bw, IM)하였다. 시험군은 상기와 같이 난소를 절제한 다음 대조시험군은 현재 국내에서 시판되고 있는 갱년기 증상 개선용 건강기능성 식품으로 저농도인 K100 (100 mg/kg) 및 고농도인 K300 (300 mg/kg)을 선택하였다.A 5-week-old female rat from SD (Sprague-Dawley) system was purchased from Sam Taco Bio Korea (Osan, Gyeonggi-do) for 4 weeks. Respectively. The black ginseng compositions of the present invention were tested by anesthesia (50 mg / kg bw, ip) with normal control, sham-operation (entobal, Hanlim Pharm) The ovariectomized group (ovariectomized group, OVX group, both ovaries were excised) and the control test groups K100 and K300 were performed under the same conditions. After the operation, all the animals were injected once (0.2 mg / kg.bw, IM) with gentamicin sulfate injection (Gentamycin, Dongshin Pharma) to prevent infection. After the ovaries were removed as described above, the test group was selected as K100 (100 mg / kg) and K300 (300 mg / kg) as low-concentration health functional food for improving the symptoms of menopausal symptoms currently marketed in Korea Respectively.
본 발명의 흑삼 조성물은 동진제약 연구소에서 공급한 저농도 흑삼 조성물 D100 (100 mg/kg)과 고농도 흑삼 조성물 D300 (300, mg/kg)으로 시험하였으며, 각 군당 공히 10마리씩 공시하였으며 실험은 모두 3개월 동안 실시하였다. 동물실의 환경은 온도(23 ± 2 ℃), 상대습도(50 ± 5 %), 및 명암주기(07:00 점등 19:00 소등)가 조절되는 환경에서 사육하였고, 음수, 사료섭취량 및 분변 등의 채취를 위하여 전 시험기간 동안 클린 랙 (clean rack)을 사용하여 각각 1마리씩 사육하였다. 음수는 여과된 정제수를 자유섭취시켰다. 본 발명에서 모든 동물실험은 대전대학교 동물실험윤리위원회 (Institutional Animal Care and Use Committee, IACUC)의 승인 하에 동 위원회의 표준작업순서 (Standard Operation Procedures, SOP)에 따라 수행되었다.
The black ginseng composition of the present invention was tested with a low-concentration black ginseng composition D100 (100 mg / kg) and a high-concentration black ginseng composition D300 (300, mg / kg) supplied by Dongjin Pharmaceutical Co., Lt; / RTI > The environment of the animal room was raised in an environment controlled by temperature (23 ± 2 ° C), relative humidity (50 ± 5%), and light period (07:00 lit 19:00 lights off), and negative water, feed intake and feces Were kept in a clean rack during the entire test period. Negative water was freely infused with filtered purified water. All animal experiments in the present invention were carried out in accordance with the Standard Operation Procedures (SOP) of the Commission, with approval of the Institutional Animal Care and Use Committee (IACUC) of Daejeon University.
체중, 사료 및 Weight, feed and 음수섭취량의Negative intake 측정 Measure
흑삼 조성물을 포함한 대조시험물질 투여군 모두 모든 동물에 대하여 시험물질 급여 개시 직전에 1회, 급여 이후에는 2주에 1회씩 3개월 동안 일정한 시간에 체중을 측정하였으며, 그리고, 부검 당일 체중을 측정하였다. 한편, 사육 케이지 별로 2주에 1회씩 3개월간 사료와 음수 소비량을 측정하여, 일일 평균 사료 섭취량 (g/animal/day)과 평균 음수 섭취량 (ml/animal/day)을 산출하였다.
For all animals in the control test substance group including the black ginseng composition, the body weight was measured at a certain time for 3 months, immediately before the start of the test substance supply and once every 2 weeks after the test, and the body weight was measured on the day of the autopsy. On the other hand, average daily feed intake (g / animal / day) and average negative water intake (ml / animal / day) were calculated by measuring feed and water consumption for 3 months once every two weeks for each cage.
혈액학적 검사Hematological examination
부검 전일 20~24시간 절식시킨 동물을 에테르 마취 하에 복대정맥으로부터 전채혈하여 얻은 혈액의 일부를 EDTA 튜브 (BD vaccutainer, USA)에 응고되지 않게 잘 보관한 다음 3시간 이내에 적혈구수 (red blood cells, RBC) 및 백혈구수 (white blood cells, WBC)를 포함한 혈액학적 검사를 자동혈액측정기 (Sysmax SE-9000, Sysmax Medical, Co., LTD., Japan)를 이용하여 수행하였다.
Blood was collected from the abdominal vein under ether anesthesia for 20-24 hours on the day before the autopsy, and a portion of the blood was stored in an EDTA tube (BD vaccutainer, USA) to prevent clotting. After 3 hours, red blood cells, (Sysmax SE-9000, Sysmax Medical, Co., Ltd., Japan) containing hematoxylin and eosin (RBC) and white blood cells (WBC)
혈액생화학적 검사Blood biochemical test
부검 전일 20∼24시간 절식시킨 동물을 에테르 마취하에, 복대정맥에서 전채혈해서 얻은 혈액을 혈청분리용 원심분리관 (SST-tube, BD vaccutainer, USA)에 넣어 실온에 30분간 방치하여 응고시킨 다음, 원심분리 (3,000 rpm × 15 min)해서 얻은 혈청에 대해서 골 지표에 관련한 혈청생화학적 지표를 포함하여 ALT (alanine transaminase), AST (aspartate transaminase), 총콜레스테롤, 중성지방 (triglycerides)을 포함한 혈액생화학적 검사를 생화학 자동분석기 (Hitachi-7180, Hitachi Medical, Co., LTD. Japan)를 이용하여 수행하였으며, 모든 실험과정과 검사법은 진단검사의학적 가이드라인에 준하여 실험하였다.
The blood obtained by collecting whole blood from the abdominal vein under ether anesthesia for 20-24 hours on the day before the autopsy was placed in a centrifuge tube for serum separation (SST-tube, BD vaccutainer, USA), allowed to stand at room temperature for 30 minutes, (3,000 rpm × 15 min), serum biochemical markers related to bone markers, and blood biochemistry including alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol and triglycerides All tests and tests were carried out in accordance with the diagnostic guideline of the medical examination. The test was carried out using a biochemical automatic analyzer (Hitachi-7180, Hitachi Medical, Co., Ltd.).
골밀도 측정Bone density measurement
실험동물 부검시 대퇴골을 골발하고 LUNAR사의 PIXIMUS TMSerise densitometer (GE LUNAR Corporate, USA)를 이용하여 골밀도 및 골함량과 골칼슘량을 각각 측정하였다.
Bone mineral density, bone mass, and bone calcium were measured using a PIXI MUS TM Serise densitometer (GE LUNAR Corporate, USA) from LUNAR.
골조직의 칼슘과 인 분석Calcium and phosphorus analysis of bone tissue
대퇴골을 550∼600℃ 회화로에서 24시간 정도 회화하여 얻은 회분을 6N HCl 용액으로 용해한 후 LaCl2로 희석하여 원저흡광도계 (AAS, GBC HG3000, GBC Scientific Equipment Pty Ltd., Australia)로 칼슘 함량을 측정하였다. 인 함량은 골조직을 회화시켜 용해한 용액을 탈이온수로 회석하여 Fisk와 Subbarow 방법을 이용하여 비색법으로 측정하였다. 한편 요중에서의 무기물 분석은 실험 종료 전주에 대사 케이지를 이용하여 24시간 뇨를 채취한 다음 여과지와 원심분리를 이용하여 불순물을 제한 다음 일반 생화학적 분석법과 동일한 방법으로 실험하였다.
The ash obtained from the femur at 550-600 ° C for 24 hours was dissolved in 6N HCl solution and diluted with LaCl 2. The calcium content was measured by the original absorbance spectrometer (AAS, GBC HG3000, GBC Scientific Equipment Pty Ltd., Australia) Respectively. Phosphorus content was measured by colorimetric method using Fisk and Subbarow method. On the other hand, the inorganic matter analysis in the urine was carried out in the same manner as the general biochemical method by limiting the impurities by using the filter paper and the centrifuge after collecting the urine for 24 hours using the metabolic cage at the end of the experiment.
혈중 호르몬과 With blood hormones 골대사Bone metabolism 지표에 미치는 효과 Effect on the Indices
골 대사의 주요 지표인 혈청 중 오스테오칼신 (osteocalcin)의 농도는 랫트 전용 오스테오칼신 ELISA 킷트 (Biomedical Technologies Inc., USA)를 이용하여 ELISA 판독기로 분석하였다. 골 용해의 주요 지표인 혈청 중 콜라겐 가교 CTx (C-terminal telopeptide)의 농도는 RatLapsTM ELISA 킷트 (Nordic bioscience diagnostics)를 이용하여 측정하였다.
The concentration of osteocalcin in serum, a key index of bone metabolism, was analyzed by ELISA reader using a rat-specific osteocalcin ELISA kit (Biomedical Technologies Inc., USA). The concentration of collagen-crosslinked CTx (C-terminal telopeptide) in the serum, which is a main index of osteolysis, was measured using a RatLaps ™ ELISA kit (Nordic bioscience diagnostics).
조직생화학적 분석Tissue biochemical analysis
Bansal 등 (1983)의 방법에 따라 적출한 랫트의 간을 잘게 썰고 150 mM KCl을 함유한 30 mM Hepes 완충액 (pH 7.4)으로 5배 희석하여 균질화한 다음 700 g로 20분간 원심분리하여 상등액을 얻었다. 그 상등액을 11,000 g로 30분간 고속원심 분리하여 펠렛을 제거하였다. 그 상등액을 다시 105,000 g로 60분간 초원심분리하여 세포질 분획을 얻었으며, 펠렛은 130 mM KCl 함유 Hepes 완충액으로 씻어낸 다음 같은 완충액으로 재균질화하여 마이크로좀 분획을 얻었다. 마이크로좀과 세포질 분획을 분리하는 전 과정은 0∼4℃의 저온실에서 수행하였으며, 조제한 분획을 -70℃에 보관하면서 SOD (superoxide dismutase), CAT (catalase), GST (glutathione-S-transferase), GSH (glutathione) 및 MDA의 실험에 각각 사용하였다. 단백질 정량은 BSA (Bovine serum albumin)를 표준물질로 사용하여 Lowry 등 (1951)의 방법에 따라 측정하였다. 한편 간 조직의 SOD 활성도는 Cropo 등의 방법, CAT의 활성도는 Aebi의 방법, GST의 활성도는 Habig 등의 방법, GSH의 함량은 Uchiyama 등의 방법과 Ellman 등의 방법에 따라 측정하였으며, MDA의 함량은 Suematsu 등 (1977)의 방법에 따라 시험관에 20% 아세트산 1.5㎖, 8.1% SDS 0.225㎖, 증류수 0.075㎖, 1.2% TBA 용액 1㎖, 그리고 간의 균질액, 세포질 또는 마이크로좀을 각각 넣었다. 반응액은 100℃로 30분 가열 후 원심분리 (3,000rpm, 10min)하여 상등액에 대하여 532㎚에서 흡광도를 측정하였으며 검량선은 MDA (malondialdehyde)를 사용하여 환산하였다. 또한 마이크로좀 막 (microsomal membrane)의 지질 과산화도를 비교하기 위하여 NADPH 0.1mM과 ADP-Fe2 +(ADP 0.5mM, Fe2 + 0.02mM)을 첨가하고 시험관에 마이크로좀을 넣은 후 각각 37℃에서 0, 5, 10, 30, 60분 반응시켜 위와 동일한 방법으로 MDA 함량 변화를 측정하였다. 모든 시험항목에 대해서는 세 번씩 반복 측정하여 각각의 농도를 구하였다.
The liver of the rat was chopped according to the method of Bansal et al. (1983), homogenized by 5 times dilution with 30 mM Hepes buffer (pH 7.4) containing 150 mM KCl, and centrifuged at 700 g for 20 minutes to obtain a supernatant . The supernatant was centrifuged at 11,000 g for 30 minutes to remove the pellet. The supernatant was again centrifuged at 105,000 g for 60 minutes to obtain a cytoplasmic fraction. The pellet was washed with Hepes buffer containing 130 mM KCl and re-homogenized with the same buffer to obtain a microsomal fraction. SOD (superoxide dismutase), CAT (catalase), GST (glutathione-S-transferase), and glutathione-S-transferase (GST) were maintained at -70 ℃. GSH (glutathione) and MDA, respectively. Protein quantification was performed according to the method of Lowry et al. (1951) using BSA (Bovine serum albumin) as a standard material. The activity of SOD in hepatic tissues was measured by Cropo et al., The activity of CAT by Aebi method, the activity of GST by Habig et al., The content of GSH by Uchiyama method and Ellman et al. Were injected with 1.5 ml of 20% acetic acid, 0.225 ml of 8.1% SDS, 0.075 ml of distilled water, 1 ml of 1.2% TBA solution, and homogenate, cytoplasm or microsomes, respectively, according to the method of Suematsu et al. (1977). The reaction solution was heated at 100 ° C for 30 minutes, centrifuged (3,000 rpm, 10 min) and the absorbance at 532 nm was measured for the supernatant. The calibration curve was converted using MDA (malondialdehyde). To compare the lipid peroxidation of microsomal membranes, NADPH 0.1 mM and ADP-Fe 2 + (ADP 0.5 mM, Fe 2 + 0.02 mM) were added and microsomes were added to the test tube. 0, 5, 10, 30, and 60 minutes, respectively. All test items were repeatedly measured three times to obtain respective concentrations.
조직학적 검사Histological examination
적출한 간, 폐, 신장, 비장, 자궁에 대하여는 우선 육안으로 관찰하고 실험 목적에 따라 구분한 후, 일반조직의 경우 자동 조직 프로세서 (automatic tissue processor; Citable 2000)를 이용하여 탈수, 투명, 파라핀 침투 과정을 거친 다음, 포매, 삭정, 박절, 염색 및 봉입하였다. 반면 골조직의 경우 오른쪽 대퇴부의 골편을 절취하여 5% 질산 (HNO3) 용액에서 2∼3일간 탈회시킨 후 에탄올 계열로 탈수하고 통상적인 방법에 따라 파라핀에 포매하여 염색한 후 검경하였다. 즉 염색은 H&E (Hematoxylin-Eosine)염색을 탈 파라핀과 함수 과정을 거친 후 수세하고 5분간 헤마토자일린으로 염색한 다음 과염색된 부분은 흐르는 수돗물로 세척 후 1% HCl/70% A/C 용액에 3-5회 담근 후 다시 흐르는 수돗물에 수세하였다. 검체는 1% 암모니아수에 5-10회 담금으로써 핵을 청화 하였다. 그 다음 5-10분 정도 충분히 수세하여 핵이 청명한 청색이 되도록 하고 세포질 대조 염색으로 염색한 다음 15초간 과도한 에오신 여액을 흐르는 물로 세척하고 탈수 및 투명 과정을 거쳤다. 다음으로 봉입을 실시한 다음 검경하였다.
The extracted liver, lung, kidney, spleen and uterus were first observed with the naked eye and classified according to the purpose of the experiment. Then, in the case of general tissue, dehydration, transparency, paraffin penetration using an automatic tissue processor (Citable 2000) , Followed by embedding, stabbing, cutting, dyeing, and sealing. On the other hand, in the case of bone tissue, the fragment of the right thigh was cut and demineralized in 5% nitric acid (HNO 3 ) solution for 2 to 3 days, dehydrated in ethanol series, embedded in paraffin according to a conventional method, and stained. The hematoxylin-Eosine (H & E) stain was washed with de-paraffin and water, washed with hematoxylin for 5 minutes, washed with flowing tap water and then washed with 1% HCl / 70% A / C After immersing in the solution 3-5 times, it was rinsed with running tap water. The samples were immersed in 1% ammonia water for 5-10 times to nucleate the nuclei. After washing for 5 to 10 minutes, the nuclei were cleared to a clear blue color, stained with cytoplasmic contrast dye, and then washed with running water for 15 seconds, followed by dehydration and clarification. Next, the bag was sealed and then examined.
통계처리Statistical processing
실험 결과는 PASW(version 19.0)을 이용하여 각 실험군마다 평균과 표준편차를 구하였고, ANOVA (One-way analysis of variance) t-test를 한 후 Duncan's multiple-range test에 의하여 각 실험군 간의 유의차를 검증하였다.
The mean and standard deviation of each test group were calculated using PASW (version 19.0) and Duncan's multiple-range test was performed after one-way analysis of variance (ANOVA) Respectively.
결과 1: 흑삼 조성물Result 1: Black ginseng composition 이this 신장 및 무기물의 변화에 미치는 영향 Effects on kidney and mineral changes
신장은 매우 복잡한 기관이지만 그 구조적 특성과 수행하는 다양한 기능은 생체의 기본적인 상태 유지를 위하여 매우 정확히 기능을 수행해야 한다. 신장은 단백질 분해산물의 최종 대사산물인 요소, 크레아티닌, 요산 등을 제거하는 기능과 체내의 항상성을 유지하는 중요한 역할을 담당하고 있다. 체내의 산, 염기의 평형 및 염도와 수분의 평형은 신장의 여과, 재흡수, 배설의 과정을 통해서 관리된다. 신장에서 가장 중요한 질환은 지표는 근위세뇨관의 손상을 볼 수 있는데 그 이유는 신장으로부터 혈액의 공급량이 많기 때문에 이로 인해 독성물질이 운반될 가능성이 크다. 또한 신장은 외부 물질의 제거뿐만 아니라 재흡수하는 기능도 있고, 무해한 물질을 반응성 있는 대사물질로 변화시킬 수 있는 혼합기능도 있다. 이러한 여러 가지 이유로 신장기능의 주요 지표로 혈액에서는 혈중 요소 질소와 크레아티닌 농도 측정은 필수적인 검사로 애용되고 있다.The kidney is a very complex organ, but its structural properties and the various functions it performs must perform very precisely to maintain the basic condition of the living body. Kidney plays an important role in maintaining the body's homeostasis and function of eliminating the end metabolites of protein degradation products such as urea, creatinine, and uric acid. Equilibrium of acids and bases in the body, and equilibrium of salinity and moisture are controlled through the processes of filtration, reabsorption and excretion of the kidneys. The most important disease in the kidney is the indicator that the damage of the proximal tubule can be seen because the supply of blood from the kidney is high, which is likely to carry toxic substances. The kidney also has the function of reabsorption as well as the removal of external substances, and the ability to change harmless substances into reactive metabolites. For many of these reasons, blood urea nitrogen and creatinine levels are a critical indicator of kidney function.
뼈는 골격의 80%를 구성하는 겉질뼈 (cortical bone)와 20%를 차지하는 해면뼈 (trabecular bone)로 이루어져 있고 해면뼈가 대사적으로 활동적이다. 뼈의 2/3는 무기질로 수산화인석 결정체와 무형의 칼슘염으로 구성되며 나머지 1/3은 기질로 이중 90%가 제1형 콜라겐이다. 성인의 골격에서는 새로운 뼈가 오래된 뼈를 대체하는 골 재형성 (bone remodeling) 과정이 끊임없이 반복된다. 골 재형성과정은 파골세포 활성기, 반전기, 조골세포에 의한 골형성기, 휴식기로 구분되며 평균 4∼6개월을 주기로 하고 개인차마다 차이가 있다. 골의 성장과 교체에 영향을 미치는 것은 칼슘, 인, 마그네슘 그리고 부감상선호르몬 등이며 이 호르몬들이 영향을 미치는 주된 기관은 뼈, 신장, 소장이다. 이 외에도 다양한 지표들이 이용되고 있다. 본 결과에서는 뼈의 주성분을 이루는 무기물과 생화학적 지표 등을 통하여 난소절제 모델에서 본 발명의 흑삼 조성물이 어떠한 영향을 미치는지 보고자 하였다.The bone consists of the cortical bone, which accounts for 80% of the skeleton, and the trabecular bone, which accounts for 20%. The sponge bone is metabolically active. Two-thirds of the bone is made up of inorganic calcium hydroxide crystals and intangible calcium salts. The remaining one-third is the matrix, 90% of which is
주요 생화학적 지표로서 칼슘과 인은 정상군과 샴군과의 비교에서 난소절제군에서는 유의하게 감소한 반면, 정상군을 포함한 시험물질 특히 흑삼 조성물 투여군 (D100 및 D300)에서는 칼슘과 인의 흡수가 유의하게 억제되었다. 이러한 결과들은 난소절제로 인하여 혈중에서 무기물질의 소실이 일어난 것으로 이는 대퇴골에서의 결과와 요중에서의 결과들을 뒷받침한다고 하겠다. 한편 신장의 주요 지표로 활용되는 크레아티닌과 BUN의 지표에서는 모든 시험군에서 유의한 변화는 관찰되지 않았다 (표 1).The major biochemical markers of calcium and phosphorus were significantly decreased in the ovariectomized group compared to the normal group and the sham group, but the calcium and phosphorus uptake was significantly inhibited in the test substance containing the normal group, especially in the black group (D100 and D300) . These results support the disappearance of inorganic substances in the blood due to ovariectomy, which supports the results in the femur and in the urine. In addition, there was no significant change in creatinine and BUN parameters in all test groups (Table 1).
결과 2: 흑삼 조성물Result 2: Black ginseng composition 이this 당 및 지질대사 변화에 미치는 영향 Effect on metabolism of sugar and lipid
혈중 콜레스테롤 조절은 여러 가지 방법으로 이루어지지만 그 중에서도 간세포에서 이루어지는 콜레스테롤 생합성의 억제가 가장 중요한 조절방법 중 하나이다. 콜레스테롤은 아세트산으로부터 20여 단계를 거쳐 합성되며 그 반응의 속도제한 단계는 HMG-CoA가 HMG-CoA 환원효소에 의해서 메발론산 (mevalonic acid)으로 되는 과정이다. 콜레스테롤은 이 단계에서 음성적 피드백 (negative feedback)으로 조절되고 있다. 고지질혈증은 동맥경화증의 지표로서 생체 내 혈중 콜레스테롤 농도의 조절기전에 장애가 있을 때 즉, 소장에서 중성지질의 합성 및 킬로미크론 (chylomicron)의 분비 증가, 간에서 중성지방의 합성 증가, VLDL 및 LDL의 합성 및 분비 증가, HDL의 합성 감소, 그리고 리파아제의 활성 감소로 인한 말초조직에서의 중성지방의 제거기능 저하 등에 의해 발생한다. 한편 본 발명에서 지질 관련 지표에서는 총 콜레스테롤, 저밀도 콜레스테롤 그리고 중성지질이 난소절제로 인하여 정상대조군에 비하여 유의하게 증가한 결과가 관찰되었다. 반면 시험물질인 흑삼 조성물 투여군 (D100 및 D300)에서는 총 콜레스테롤과 고밀도 및 저밀도 콜레스테롤이 유의하게 감소한 결과를 보였고, 흑삼 조성물 투여군은 대조시험물질 투여군 (K100 및 K300)과 비교하더라도 총 콜레스테롤, 저밀도 콜레스테롤 그리고 중성지질이 유의하게 억제되는 결과를 나타내었다 (표 2, 도 2).Control of blood cholesterol is accomplished by various methods, among which inhibition of cholesterol biosynthesis in hepatocytes is one of the most important control methods. Cholesterol is synthesized from acetic acid in over 20 steps and the rate limiting step of the reaction is the process by which HMG-CoA is converted to mevalonic acid by HMG-CoA reductase. Cholesterol is being regulated by negative feedback at this stage. Hyperlipidemia is an indicator of atherosclerosis, which is an indicator of atherosclerosis when there is a disturbance before the regulator of in vivo blood cholesterol concentration, that is, synthesis of neutrophil and secretion of chylomicron in the small intestine, increase of synthesis of triglyceride in the liver, synthesis of VLDL and LDL And increased secretion, decreased synthesis of HDL, and reduced lipid peroxidation in peripheral tissues due to reduced lipase activity. Meanwhile, in the lipid-related index of the present invention, total cholesterol, low-density cholesterol and triglyceride were significantly increased due to ovariectomy compared with the normal control group. On the other hand, total cholesterol, high density and low density cholesterol were significantly decreased in the group treated with black ginseng (D100 and D300), and the total cholesterol, low density cholesterol and low density cholesterol And neutral lipid was significantly inhibited (Table 2, Fig. 2).
결과 3: 흑삼 조성물Result 3: Black ginseng composition 이this 간 기능지표에 미치는 영향 Effect on liver function index
간 기능지표에서는 정상대조군 대비 난소절제군 모두에서 총 단백과 알부민이 유의하게 감소하는 경향을 보였다 (p<0.05). ALP의 활성 농도는 정상대조군 대비 난소절제군에서 유의하게 증가하였다. 그러나 시험군 모두에서 억제되는 현상은 관찰되지 않았다. ALP는 골형성 활동의 중요한 지표가 되는 것으로 골아세포에 존재하며, 골 신생이 활발하게 진행될 때 혈중 농도가 증가하게 되는데, 폐경 후, 골다공증, 골절 환자와 성장기 초기 그리고 Ca 결핍시 증가한다는 보고가 있다. 다른 선행연구결과에서는 SD계 암컷 흰쥐를 대상으로 난소절제군이 개복수술만을 시행한 샴군에 비해 ALP 농도가 높게 나타난 것으로 보고하였다. 그 이유는 난소절제로 인하여 골 대사 (bone turnover)가 증가되었기 때문으로 해석되고 있다. 본 발명에서도 정상군에 비하여 난소절제군의 혈청 ALP의 농도가 증가하였고, 본 발명의 시험물질인 흑삼 조성물 처리군에서도 ALP의 증가가 일부 억제되는 경향을 보였다. 한편 간 기능의 주요 지표인 AST/ ALT의 변화에서는 정상대조군 대비 난소를 절제한 경우에 간 기능의 저하가 유의하게 관찰되었다. AST와 ALT는 간세포의 손상을 반영하는 중요한 효소로서 가장 기본적인 간기능 검사의 중요한 항목이다. 두 효소는 모두 보조인자로서 인산피리독살 (비타민 B6)을 필요로 한다. ALT를 예를 들면 알라닌은 인산피리독살과 반응하여 피르부산염과 피리독신을 생성한다. 그뒤 피리독신은 알파케토글루타레이트와 반응하여 글루탄산염과 인산피리독살을 재생한다. AST와 ALT의 반감기는 각각 17시간과 47시간이며, ALT는 모두 사립체 밖에 존재하는데 반해 AST는 사립체의 밖과 안에 모두 존재한다. 사림체성 AST의 반감기는 87시간이다. AST는 심장, 근육, 혈구 등을 포함하여 체내 대부분에 존재하는데 반해 ALT는 주로 간에만 존재하며, 신장에도 상당량이 존재한다. 일반적으로 실험에서의 이 두 지표의 해석은 AST는 혈장에서 7,000배, ALT는 약 3,000배 정도로 많이 존재한다. 본 실험에서와 같이 비알콜성 실험일 경우 AST와 ALT를 해석함에 있어 ALT가 더 특이적이기는 하나 AST 또한 중요한 지표로 해석되고 있다. 그 이유는 AST가 간장을 포함한 신체의 여러 장기에 널리 분포되어 있으므로 일반적인 동물실험에서는 모두 효과적이라고 할 수 있다.In liver function index, total protein and albumin tended to decrease significantly in all ovariectomized group compared to normal control group (p <0.05). ALP activity was significantly increased in the ovariectomized group compared to the normal control group. However, no inhibition was observed in both groups. ALP is an important index of osteogenesis activity and is present in osteoblasts. When osteoblasts are actively activated, serum concentration is increased. It is reported that ALP is increased in postmenopausal, osteoporotic, fractured patients, early growth period and Ca deficiency . Other preliminary results reported that ovariectomized group had higher ALP levels in SD group female rats compared to the sham group who performed only open surgery. The reason for this is interpreted as the increase in bone turnover due to ovariectomy. In the present invention, the serum ALP concentration in the ovariectomized group was increased compared with the normal group, and the increase in ALP also tended to be partially suppressed in the group treated with the black ginseng composition of the present invention. On the other hand, the change of AST / ALT, which is the main index of liver function, showed a significant decrease in liver function when ovariectomized compared to normal control. AST and ALT are important enzymes that reflect hepatocyte damage and are an important element of the most basic liver function tests. Both enzymes require pyridoxal phosphate (vitamin B6) as cofactor. ALT, for example, reacts with pyridoxal phosphate to produce pyridinium salts and pyridoxine. Subsequently, pyridoxine reacts with alpha ketoglutarate to regenerate glutarate and phosphate pyridoxal. The half-lives of AST and ALT are 17 hours and 47 hours, respectively, while ALT is outside of mitochondria, whereas AST exists both inside and outside of mitochondria. The half-life of sporadic AST is 87 hours. AST is present in most parts of the body including heart, muscle, blood cells, etc. ALT is mainly present only in the liver, and there is also a large amount in the kidney. In general, the interpretation of these two indicators in the experiment is as many as 7,000 times in plasma and about 3,000 times in ALT. As in this experiment, AST is interpreted as an important index in analyzing AST and ALT in nonalcoholic experiments, although ALT is more specific. The reason is that AST is widely distributed in various organs of the body including the liver, so it is effective in general animal experiments.
간기능의 주요 지표인 AST와 ALT는 난소 절제군에서 유의하게 증가한 반면, AST는 정상군을 포함한 다른 시험물질 투여군에서는 정상적으로 화복되었다. 그러나 ALT는 정상군과의 비교에서 억제되는 경향은 보이나 통계적으로 유의성은 관찰되지 않았다 (표 3). 이러한 결과들은 흑삼 조성물 또는 대조시험물질이 난소절제로 인한 저하된 간의 기능을 정상적으로 회복시켜 주는 데에 있어 중요하게 작용하고 있음을 시사한다고 하겠다.AST and ALT, the main indicators of liver function, were significantly elevated in the ovariectomized group, whereas AST was normalized in the other test substance-containing groups. However, ALT tended to be suppressed in comparison with the normal group, but no statistical significance was observed (Table 3). These results suggest that the black ginseng composition or the control test substance plays an important role in restoring normal liver function due to ovariectomy.
결과 4: 흑삼 조성물이 골밀도에 미치는 영향Result 4: Effect of black ginseng composition on bone mineral density
난소를 절제한 흰쥐에 흑삼 조성물과 대조시험물질을 12주간 매일 투여하면서 각 군의 대퇴골에서 골밀도를 측정하여 도 1에 나타내었다. 그 결과 정상군에 비해 난소절제군 (OVX), 샴군 (sham)과 대조시험물질 투여군 (K100 및 K300)과 시험물질 투여군 (D100 및 D300)에서 골밀도 값이 유의하게 감소하는 것을 확인할 수 있었다. 반면에 난소절제군을 포함하여 샴군과 대조시험물질 투여군에서의 값이 난소절제군에 비하여 유의하게 증가하는 것을 알 수 있었다 (도 1). Tsuchida 등(1999)은 일본에서 중년과 폐경 후 여성의 대두 섭취량이 골밀도와 유의적인 양의 상관관계를 보였다고 보고하였고, 한국에서도 홍삼의 섭취가 폐경 후 골다공증 여성의 골밀도를 증가시키며, 골용해를 낮추는 등 골밀도와 골대사에 긍정적인 영향을 주고 있는 것으로 보고되고 있다. 본 발명의 시험물질인 흑삼 조성물 투여군에서는 골밀도가 향상되는 경향을 나타내었고, 특히 저농도 및 고농도 흑삼 조성물 투여군 모두에서 골밀도가 유의한 증가를 보였는데, 이는 본 발명의 흑삼 조성물이 난소절제에 따른 골 소실을 막아줌으로써 폐경기 여성들에게서 빈번하게 발생하는 골다공증 예방에 효과적인 조성물인 것으로 사료된다.
The bone mineral density was measured in the femur of each group while the black ginseng composition and the control test substance were daily administered to the ovariectomized rats for 12 weeks, and it is shown in Fig. As a result, the bone mineral density values were significantly decreased in OVX, sham, control test group (K100 and K300) and test substance treated group (D100 and D300) compared to normal group. On the other hand, the values in the sham group and the control test substance administration group including the ovariectomized group were significantly increased compared to the ovariectomized group (Fig. 1). Tsuchida et al. (1999) reported that the intake of soybeans in middle-aged and postmenopausal women showed a significant positive correlation with bone mineral density in Japan. In Korea, the consumption of red ginseng increases bone mineral density in postmenopausal women with osteoporosis, And bone mineral density (BMD). The bone mineral density of the group administered with the black ginseng composition of the present invention tended to be improved, and the bone density of the black ginseng composition of the present invention was significantly increased in both the low and high concentration groups. It is considered to be an effective composition for preventing osteoporosis frequently occurring in postmenopausal women.
결과 5: 흑삼 조성물Result 5: Black ginseng composition 이this 대퇴골에서 골 무기물에 미치는 영향 Effect of bone mineral content on femur
대퇴골 중의 회분 함량의 변화를 보면, 난소절제군에서는 411±32.6 mg로 정상군에 비하여 유의성 있게 감소하였다 (p<0.05). 반면, 본 발명의 흑삼 조성물 D300 투여군에서는 대퇴골 중 회분 함량이 난소절제군에 비하여 유의성 있게 증가하였다 (p<0.05). 대퇴골의 칼슘과 회분의 함량은 표 5와 같다. 대퇴골 중 칼슘 함량 변화를 보면, 난소절제군에서는 127±10.5 mg으로 정상군에 비하여 유의성 있게 감소하였다 (p<0.05). 반면에 칼슘이 없는 기본사료에 흑삼 조성물질 저농도 투여군에서 133±9.5 mg으로 난소절제군에 비하여 유의하게 증가하였다 (p<0.05). 반면 대퇴골 중 인의 함량은 난소절제군을 포함하여 흑삼 조성물을 포함한 대조물질 투여군 모두에서 각각 유의하게 억제된 (p<0.05) 반면, 난소절제군 대비 고농도 흑삼 조성물 D300 투여군에서 유의하게 억제되는 경향 (p<0.05)을 보였다 (표 4, 도 3).The changes in ash content in the femur were 411 ± 32.6 mg in the ovariectomized group (p <0.05). On the other hand, in the group treated with the black ginseng D300 according to the present invention, the ash content in the femur was significantly increased compared to the ovariectomized group (p <0.05). Table 5 shows the contents of calcium and ash in the femur. The calcium content in the femur was 127 ± 10.5 mg in the ovariectomized group (p <0.05). On the other hand, the amount of calcium-free basic diet was significantly increased (133 ± 9.5 mg) compared to ovariectomized group (p <0.05). In contrast, the content of phosphorus in the femur was significantly inhibited (p <0.05) in both the control group and the control group including the ovariectomized group, while it was significantly inhibited in the group treated with the high concentration black ginseng D300 ≪ 0.05) (Table 4, Fig. 3).
결과 6: 흑삼 조성물Result 6: Black ginseng composition 이this 요중에서In the urine 골 무기질과 Bone minerals DpdDpd 에 미치는 영향Effect on
뇨 중에서 칼슘 함량은 정상대조군과 샴군에 비해 유의하게 증가하였으며, 반면 난소절제군 대비 시험물질 투여군에서는 유의하게 억제되는 결과를 보였다. 한편 뇨 중에서의 인의 함량 역시 칼슘 (p<0.05~0.01)과 같은 결과를 보였다. 한편 뇨 중에서의 Dpd(deoxypyridinoline)는 정상대조군을 포함한 샴군과의 비교에서 난소절제군과 흑삼 조성물 투여군에서 유의하게 증가한 반면, 난소절제군 대비 대조시험물질 투여군에서는 Dpd가 억제되는 경향을 보였으며 그 외 투여군에서는 감소하는 경향을 보였으나 통계적 유의성은 인정되지 않았다 (표 5, 도 4).Calcium content in urine was significantly increased compared with normal control group and sham group, but it was significantly inhibited in test group compared to ovariectomized group. The content of phosphorus in urine was also the same as that of calcium (p <0.05 ~ 0.01). On the other hand, Dpd (deoxypyridinoline) in urine was significantly increased in the ovariectomized group and the black ginseng-treated group compared with the sham group including the normal control group, whereas Dpd was suppressed in the control group-administered group compared to the ovariectomized group But there was no statistical significance (Table 5, Fig. 4).
결과 7: 흑삼 조성물Result 7: Black ginseng composition 이this 혈중 호르몬과 With blood hormones 골대사Bone metabolism 지표에 미치는 영향 Impact on the Indices
에스트라다이올(Estradiol)은 주요한 에스트로겐 호르몬으로 에스트로겐의 가장 주요한 활성형이다. 에스트라다이올 측정은 사춘기의 지연, 무월경 및 폐경기의 경우를 진단하는데 가장 중요한 지표 중 하나이다. 또한 에스트라다이올 및 에스트로겐이 감소하면 골 흡수가 증가하고, 소화관에서 칼슘 흡수가 저하되어 폐경 후 골다공증과 관련되어 있다고 알려져 있다. 본 실시예에서는 정상대조군 대비 난소절제군을 포함하여 흑삼 조성물 투여군 그리고 대조시험물질 투여군 모두에서 에스트라다이올이 유의하게 감소한 (p<0.05~0.01) 반면, 난소절제군 대비 시험물질 투여군 모두에서 에스트라다이올이 유의하게 증가하였다 (p<0.05~0.01). 한편 난소를 절제한 랫트에 흑삼 조성물과 대조시험물질을 매일 투여하면서 12주 후 각 군의 혈청 중 오스테오칼신(osteocalcin)의 함량을 측정한 결과를 표 6에 나타내었다. 혈청 중 오스테오칼신 함량은 난소절제군에서 39.6±3.46 ng/mL로 정상군에 비해 유의하게 증가하였고(p<0.05), 반면 흑삼 조성물 고농도 투여군인 D300군은 28.4±1.15 ng/mL, 저농도 투여군에서는 28.5±1.25 ng/mL, 그리고 대조시험물질 투여군은 고농도와 저농도에서 각각 31.4±1.35 ng/mL과 32.6±2.93 ng/mL로 나타나 난소절제군에 비하여 흑삼 조성물 고농도 투여군에서만 유의한 감소를 (p<0.05) 보인 반면, 그 외 투여군에서는 감소하는 경향은 관찰되었으나 통계적인 유의성은 관찰되지 않았다. 현재의 결과로 볼 때 흑삼 조성물 투여군에서 대조시험물질 투여군과의 비교에서 유의한 차이가 관찰되었다. 한편 황체형성 호르몬의 변화에 있어서는 정상대조군을 포함하여 샴군을 포함하여 난소절제군 그리고 흑삼 조성물을 포함한 대조시험물질 모두에서 어떠한 변화도 관찰되지 않아 다른 선행연구결과들과 일치하는 결과를 보였다. 다만 난소절제군에서 증가하는 경향을 보였으나 통계적인 유의한 차이는 관찰되지 않았다.Estradiol is a major estrogen hormone and the most active form of estrogen. Estradiol measurements are one of the most important indicators for the diagnosis of delayed puberty, amenorrhea and menopause. It is also known that decreasing estradiol or estrogen increases bone resorption and decreases calcium absorption in the digestive tract and is associated with postmenopausal osteoporosis. In this example, estradiol was significantly decreased (p < 0.05-0.01) in both the black gum composition administration group and the control test substance administration group including the ovariectomized group compared to the normal control group, whereas estradiol (P < 0.05 to 0.01). On the other hand, the content of osteocalcin in the serum of each group was measured 12 weeks after the daily administration of the black ginseng composition and the control test substance in the ovariectomized rats, and the results are shown in Table 6. Serum osteocalcin levels were significantly increased in the ovariectomized group (39.6 ± 3.46 ng / mL, p <0.05) compared to the normal group, whereas the D300 group and 28.3 ± 1.15 ng / ± 1.25 ng / mL, and 31.4 ± 1.35 ng / mL and 32.6 ± 2.93 ng / mL, respectively, in the high and low concentrations of the test substance group, respectively (p <0.05 ), Whereas there was a tendency to decrease in other treatment groups, but no statistical significance was observed. From the present results, there was a significant difference in the comparison with the control test substance administration group in the black ginseng composition administration group. On the other hand, changes in luteinizing hormone were observed in all control subjects including ovariectomized group including control group, ovariectomized group including sham group, and control specimen including black ginseng composition. However, there was no statistically significant difference in the ovariectomized group.
오스테오칼신은 칼슘과 결합하는 비타민 K 의존성 α-카복시글루탐산(α-carboxy glutamic acid) 단백질로서 조골세포에 의해 생성되어 70%는 골 기질에 축적되고, 30% 정도는 혈액 속으로 분비되어 골 형성의 정도를 예측할 수 있는 생화학 지표로 사용되고 있다. 선행연구들에 의하면 젊은 연령층에서의 오스테오칼신의 농도 증가는 골 형성 증가를 의미하지만, 폐경 후에는 골 소실을 잘 예측할 수 있는 지표로 이용되고 있다고 한다. Byun 등은 어린 쥐에서 난소절제로 유도된 에스트로겐 결핍은 혈중 오스테오칼신 농도를 증가시키고, 이소플라본 보충으로 혈중 오스테오칼신 농도가 감소되었음을 보고하였고, 이는 실험대조군에서 오스테오칼신이 유의하게 감소를 보인 Kim 등의 연구와 일치하는 결과를 보였다. 본 발명에서도 난소절제군의 혈중 오스테오칼신의 농도는 증가하였고, 난소절제군에 비해 흑삼 조성물 투여군에서 유의적인 감소를 나타내어 흑삼 조성물이 골 교체율을 감소시켜 골흡수를 억제함으로써 골 보호 효과를 나타낸 것으로 사료된다. 또한 최근 골대사지표에서 널리 쓰이고 있는 지표인 NTx에서는 다른 선행연구의 결과와 같이 정상대조군과 샴군에 비하여 난소절제군에서 유의하게 증가한 반면, 난소절제군 대비 시험물질 투여군에서는 모두 유의하게 억제되는 결과를 보였다 (표 6, 도 5).Osteocalcin is a vitamin K-dependent α-carboxy glutamic acid protein that binds to calcium and is produced by osteoblasts, 70% is accumulated in the bone matrix, 30% is secreted into the blood, Is used as a biochemical indicator for predicting outcome. Previous studies have shown that increased levels of osteocalcin in younger age groups are associated with increased bone formation, but are used as predictors of bone loss after menopause. Byun et al. Reported that estrogen deprivation induced by ovariectomy in young rats increased osteocalcin concentration in the blood and decreased osteocalcin concentration in the blood by isoflavone supplementation, suggesting that osteocalcin was significantly reduced in experimental control, The results were consistent. In the present invention, the concentration of osteocalcin in the ovariectomized group was increased and the black ginseng composition showed a significant decrease in the group administered with the black gum composition compared to the ovariectomized group, so that the black gum composition showed a bone protecting effect by suppressing the bone resorption by decreasing the bone turnover rate . In addition, NTx, a widely used index in recent bone metabolism indexes, was significantly increased in the ovariectomized group compared to the normal control group and the sham group, but was significantly inhibited in the test substance group compared to the ovariectomized group (Table 6, Fig. 5).
결과 8: 흑삼 조성물Result 8: Black ginseng composition 이this 사이토카인의 농도에 미치는 영향 Effect on cytokine concentration
사이토카인 IL-6와 TNF-α 모두 난소절제군에서 유의하게 증가하였고 반면 시험물질 처리군에서는 IL-6의 경우 흑삼 조성물 고농도 투여군 (D300)에서는 유의한 억제효과를 보인 반면, 다른 시험물질 투여군에서는 유의한 경향은 관찰되지 않았다. 한편 TNF-α는 흑삼 투여군과 대조시험물질 투여군 모두에서 유의하게 억제되었다. 이러한 결과들은 난소절제에 의하여 사이토카인이 증가하는 것을 흑삼 조성물이 유의하게 억제함을 말해 준다 (표 7, 도 6).Both cytokine IL-6 and TNF-α were significantly increased in the ovariectomized group, whereas IL-6 in the test substance treated group showed a significant inhibitory effect in the high concentration group of black ginseng composition (D300) No significant trends were observed. On the other hand, TNF-α was significantly inhibited in both the group treated with black ginseng and the control group. These results indicate that the black ginseng composition significantly inhibits the increase of cytokine by ovariectomy (Table 7, Fig. 6).
결과 9: 흑삼 조성물Result 9: Black ginseng composition 이this 항산화 및 지질과산화의 농도에 미치는 영향 Antioxidant and lipid peroxidation
정상대조군 대비 SOD, CAT, GST, GSH, GSH-Px 그리고 MDA 모두에서 난소절제군에서 유의한 증가와 감소를 보였다 (p<0.05∼0.01). 그러나 시험물질의 투여에 대한 효과에서는 항산화 관련 지표에서는 흑삼 조성물 고농도 급여군 (D300)에서 효과를 보인 반면, GST 지표에서는 흑삼 조성물 투여군에서 난소절제군 대비 억제되는 결과를 보였다. 지질 과산화에서도 같은 결과 (p<0.05)가 관찰되었다 (표 8, 도 7, 표 9, 도 8).SOD, CAT, GST, GSH, GSH-Px and MDA were significantly increased and decreased in the ovariectomized group compared to the normal control group (p <0.05-0.01). However, in the effect of test substance administration, the antioxidant - related indicator showed an effect in the high concentration group of black ginseng composition (D300), whereas the GST index showed a suppression effect in the black ginseng composition administration group compared to the ovariectomized group. The same result (p <0.05) was also observed in lipid peroxidation (Table 8, Fig. 7, Table 9, Fig. 8).
Claims (3)
The extracts of black ginseng, gamma linolenic acid, isoflavone, Angelica gigas Nakai, peony root, pine needle, dandelion, purple ginseng, cinnamon, cinnamon, red ginseng, A health functional food composition for improving the symptoms of female menopausal symptoms.
진세노사이드 Rg1, Rb1, Rg3의 합이 6 ㎎/g 이상인 흑삼 농축액 5~30중량%,
감마리놀렌산 20~40중량%,
이소플라본 2~6중량%,
당귀, 천궁, 작약, 숙지황, 진피, 갈근, 황기, 계피, 단삼, 백하수오 및 애엽 각 추출물 1~5중량%를 포함하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물.
The method according to claim 1,
5 to 30% by weight of a black ginseng concentrate having a sum of ginsenosides Rg1, Rb1 and Rg3 of 6 mg / g or more,
20 to 40% by weight of gamma linolenic acid,
2 to 6% by weight of isoflavone,
A health functional food composition for improving female menopausal symptoms, comprising 1 to 5% by weight of an extract of Angelica keiskei, Angelica keiskei, Peony root, Silla lupus, Dermis, Puerariae radix, Cinnamon, Cinnamon,
상기 조성물에는 대두유가 더 포함되는 것을 특징으로 하는 여성 갱년기 증상 개선용 건강기능성 식품 조성물.The method according to claim 1 or 2,
Wherein the composition further comprises soybean oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140149690A KR20160058212A (en) | 2014-10-31 | 2014-10-31 | Health supplements composition containing concentrated black ginseng for menopausal women |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140149690A KR20160058212A (en) | 2014-10-31 | 2014-10-31 | Health supplements composition containing concentrated black ginseng for menopausal women |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160058212A true KR20160058212A (en) | 2016-05-25 |
Family
ID=56114180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140149690A Ceased KR20160058212A (en) | 2014-10-31 | 2014-10-31 | Health supplements composition containing concentrated black ginseng for menopausal women |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160058212A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107354006A (en) * | 2017-08-03 | 2017-11-17 | 安徽省雷氏农业科技有限公司 | Preservative preserved for peony seed oil and preparation method thereof |
| WO2019083168A1 (en) | 2017-10-27 | 2019-05-02 | 한약진흥재단 | Antithrombotic composition containing polygonum cuspidatum sieb. et zucc. and cinnamomum cassia blume |
| KR20190092831A (en) | 2018-01-31 | 2019-08-08 | 주식회사 노브메타파마 | Composition for preventing and improving woman climacterium symptoms comprising extract of Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume |
| KR102014824B1 (en) * | 2018-05-09 | 2019-08-28 | 주식회사 진생바이팜 | Health food composition for vascular relaxation and anti-thrombotic effects comprising Black Ginseng Radix, Salviae Miltiorrhizae Radix, Leonuri Herba and Cnidii Rhizoma |
| KR20190107894A (en) | 2018-03-13 | 2019-09-23 | 주식회사 케이오씨바이오텍 | Composition for preventing and improving woman climacterium symptoms comprising Glycine soja seed |
| KR20190110229A (en) * | 2018-03-20 | 2019-09-30 | 천지인초 주식회사 | A composition containing natural materials extract as an active ingredient for treatment of menopause symptoms, and manufacturing method of the same |
| KR20200011768A (en) * | 2018-07-25 | 2020-02-04 | 주식회사 해와 솔 | Ginseng mixed concentrate composition for promoting absorption of saponin |
| KR20210075488A (en) * | 2019-12-13 | 2021-06-23 | 주식회사 봄헬스케어 | Food Composition for Spayed Companion Animal |
| JP2022534014A (en) * | 2019-05-20 | 2022-07-27 | シージェイ チェイルジェダン コーポレーション | Anti-influenza virus composition, composition for treating respiratory disease and anti-aging composition containing black ginseng extract |
| JP7584892B2 (en) | 2019-12-26 | 2024-11-18 | 小林製薬株式会社 | Muscle mass loss improvement agent |
-
2014
- 2014-10-31 KR KR1020140149690A patent/KR20160058212A/en not_active Ceased
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107354006A (en) * | 2017-08-03 | 2017-11-17 | 安徽省雷氏农业科技有限公司 | Preservative preserved for peony seed oil and preparation method thereof |
| CN107354006B (en) * | 2017-08-03 | 2020-10-16 | 安徽飞镖知识产权服务股份有限公司 | Preservative for preservation of peony seed oil and preparation method thereof |
| WO2019083168A1 (en) | 2017-10-27 | 2019-05-02 | 한약진흥재단 | Antithrombotic composition containing polygonum cuspidatum sieb. et zucc. and cinnamomum cassia blume |
| KR20190047359A (en) | 2017-10-27 | 2019-05-08 | 주식회사 노브메타파마 | Anti-thrombus agent comprising extract of Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume |
| KR20190092831A (en) | 2018-01-31 | 2019-08-08 | 주식회사 노브메타파마 | Composition for preventing and improving woman climacterium symptoms comprising extract of Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume |
| KR20190107894A (en) | 2018-03-13 | 2019-09-23 | 주식회사 케이오씨바이오텍 | Composition for preventing and improving woman climacterium symptoms comprising Glycine soja seed |
| KR20190110229A (en) * | 2018-03-20 | 2019-09-30 | 천지인초 주식회사 | A composition containing natural materials extract as an active ingredient for treatment of menopause symptoms, and manufacturing method of the same |
| KR102014824B1 (en) * | 2018-05-09 | 2019-08-28 | 주식회사 진생바이팜 | Health food composition for vascular relaxation and anti-thrombotic effects comprising Black Ginseng Radix, Salviae Miltiorrhizae Radix, Leonuri Herba and Cnidii Rhizoma |
| KR20200011768A (en) * | 2018-07-25 | 2020-02-04 | 주식회사 해와 솔 | Ginseng mixed concentrate composition for promoting absorption of saponin |
| JP2022534014A (en) * | 2019-05-20 | 2022-07-27 | シージェイ チェイルジェダン コーポレーション | Anti-influenza virus composition, composition for treating respiratory disease and anti-aging composition containing black ginseng extract |
| KR20210075488A (en) * | 2019-12-13 | 2021-06-23 | 주식회사 봄헬스케어 | Food Composition for Spayed Companion Animal |
| JP7584892B2 (en) | 2019-12-26 | 2024-11-18 | 小林製薬株式会社 | Muscle mass loss improvement agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160058212A (en) | Health supplements composition containing concentrated black ginseng for menopausal women | |
| Luqman et al. | Experimental assessment of Moringa oleifera leaf and fruit for its antistress, antioxidant, and scavenging potential using in vitro and in vivo assays | |
| KR20140022648A (en) | Composition of antiobesity containing lycium chinensis leaf extract powder and betaine as effective ingredients | |
| Elhassaneen et al. | Effect of some plant parts powder on obesity complications of obese rats | |
| Singh et al. | Effects of fenugreek seeds on cardiovascular diseases and other chronic diseases | |
| KR20100109697A (en) | Functional composition with the effects of improving hyperlipidemia and reducing body weight | |
| Zaahkouk et al. | Anti–diabetic properties of water and ethanolic extracts of Balanites aegyptiaca fruits flesh in senile diabetic rats | |
| KR20090089815A (en) | A composition for enhancing athletic performance, fatigue recovery and antioxidant activity, containing a mixture of leaf extracts of Panax plants and processed extracts of leaf extracts of Panax plants | |
| KR20040084168A (en) | Use of pinitol or chiro-inositol for preventing or treating liver diseases | |
| JPH06183985A (en) | Preventive and therapeutic agent for bone resorption disease | |
| Mushtaq et al. | Evaluation of hypolipidemic activity of Allium schoenoprasum in Albino Rats | |
| KR100696589B1 (en) | Hangover Relief and Liver Protection Compositions Containing Catechin Constituents | |
| Ubah et al. | Vernonia amygdalina leaves incorporation into high fat diet exhibited hypoglycemic, hepatoprotective, and weight lowering effects in monosodium glutamate intoxicated wistar rats | |
| KR101124368B1 (en) | Functional foods comprising an alternation material for estrogenic activity by silkworm(Bombyx Mori) pupa water extracts | |
| Djétouan et al. | The Effect Of Ivory Coast Garcinia Kola Heckel (Guttiferae) Seeds on Hyperlipidemia, Hyperglycemia and Obesity in Wistar Rats | |
| WO2019146790A1 (en) | Food composition for ameliorating or preventing lifestyle-related diseases | |
| KR20160051658A (en) | Composition for Effect of Protecting Liver Cells and Increasing Bone Density Using Germinated Fermented Soybean Extract Containing | |
| Al-badry et al. | Efficacy of pomegranate peel (Punica granatum) extract on gastric ulceration induced experimental rats. | |
| KR101539057B1 (en) | Beverage composition with the extract of Acer tegmentosum Maxim. for improving liver function | |
| Eid et al. | Hypolipidemic effect of triphala (Terminalia chebula, Terminalia belerica and Emblica officinalis) on female albino rats. | |
| KR20190118270A (en) | Hepatoprotective Composition Comprising Abeliophyllum Distichum Extract | |
| KR101731898B1 (en) | Anchovy calcium products of senior-friendly using oriental medicinal herb | |
| Mustari et al. | Growth performance, hematological parameters and lipid profile of mice treated with black seed oil and vitamin-E | |
| KR20240177113A (en) | Composition for preventing, improving or treating bone disease comprising complex extract of old antler and Glycine max (L.) Merrill | |
| Deshmukh et al. | Dietary Supplements and Nutraceuticals in the Management of Endocrine Disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20141031 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160419 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170105 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20160419 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |